4.7 Article

Palmitoylation of human FasL modulates its cell death-inducing function

Journal

CELL DEATH & DISEASE
Volume 1, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/cddis.2010.62

Keywords

Fas ligand; proteolysis; ADAM10 processing; rafts; palmitoylation

Categories

Funding

  1. Centre National de la Recherche Scientifique (CNRS)
  2. Ligue nationale contre le cancer (LNCC)
  3. Association pour la Recherche contre le Cancer (ARC)
  4. Institut National du Cancer (INCa)
  5. Agence Nationale de la Recherche [ANR-08-PCVI-0034-01]
  6. German Research Foundation [ZO110/4-1, ZO110/2-1/2]
  7. German National Academic Foundation
  8. Agence Nationale de la Recherche (ANR) [ANR-08-PCVI-0034] Funding Source: Agence Nationale de la Recherche (ANR)

Ask authors/readers for more resources

Fas ligand (FasL) is a transmembrane protein that regulates cell death in Fas-bearing cells. FasL-mediated cell death is essential for immune system homeostasis and the elimination of viral or transformed cells. Because of its potent cytotoxic activity, FasL expression at the cell surface is tightly regulated, for example, via processing by ADAM10 and SPPL2a generating soluble FasL and the intracellular fragments APL (ADAM10-processed FasL form) and SPA (SPPL2a-processed APL). In this study, we report that FasL processing by ADAM10 counteracts Fas-mediated cell death and is strictly regulated by membrane localization, interactions and modifications of FasL. According to our observations, FasL processing occurs preferentially within cholesterol and sphingolipid-rich nanodomains (rafts) where efficient Fas-FasL contact occurs, Fas receptor and FasL interaction is also required for efficient FasL processing, and FasL palmitoylation, which occurs within its transmembrane domain, is critical for efficient FasL-mediated killing and FasL processing. Cell Death and Disease (2010) 1, e88; doi: 10.1038/cddis.2010.62; published online 21 October 2010

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Radiology, Nuclear Medicine & Medical Imaging

Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma

Justin Ferdinandus, Wolfgang P. Fendler, Katharina Lueckerath, Christoph Berliner, Sabine Kurzidem, Eva Hadaschik, Joachim Klode, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf, Ken Herrmann, Juergen C. Becker, Selma Ugurel

Summary: For patients with Merkel cell carcinoma (MCC) who are refractory to immune checkpoint inhibition (ICI), treatment options are limited. Combination therapy with peptide receptor radionuclide therapy (PRRT) and immune checkpoint inhibitors (ICI) may be an effective treatment option.

JOURNAL OF NUCLEAR MEDICINE (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice

Jasmin M. Klose, Jasmin Wosniack, Janette Iking, Magdalena Staniszewska, Fadi Zarrad, Marija Trajkovic-Arsic, Ken Herrmann, Pedro Fragoso Costa, Katharina Lueckerath, Wolfgang P. Fendler

Summary: The study assessed the biodistribution of various radioligand application routes in mice, and found that subcutaneous and intraperitoneal administration had comparable biodistribution to intravenous injection. Subcutaneous administration resulted in the highest tumor uptake, suggesting its potential in clinical assessment.

JOURNAL OF NUCLEAR MEDICINE (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis

Lukas Kessler, Justin Ferdinandus, Nader Hirmas, Fadi Zarrad, Michael Nader, David Kersting, Manuel Weber, Sandra Kazek, Miriam Sraieb, Rainer Hamacher, Katharina Lueckerath, Lale Umutlu, Wolfgang P. Fendler, Christoph Rischpler

Summary: This study summarizes common findings and potential pitfalls in Ga-68-FAPI PET/CT. Common findings include uptake in degenerative lesions and head-and-neck. Pitfalls include non-tumor-specific uptake in degenerative lesions, muscle, scarring, mammary glands, or uterus.

JOURNAL OF NUCLEAR MEDICINE (2022)

Article Multidisciplinary Sciences

Experimental evidence for long-distance electrodynamic intermolecular forces

Mathias Lechelon, Yoann Meriguet, Matteo Gori, Sandra Ruffenach, Ilaria Nardecchia, Elena Floriani, Dominique Coquillat, Frederic Teppe, Sebastien Mailfert, Didier Marguet, Pierre Ferrier, Luca Varani, James Sturgis, Jeremie Torres, Marco Pettini

Summary: In this study, the activation of resonant electrodynamic intermolecular forces was experimentally demonstrated using two independent experiments based on different physical effects detected by fluorescence correlation spectroscopy and terahertz spectroscopy, respectively. This discovery has significant implications for our understanding of biomolecular interactions and cellular dynamics.

SCIENCE ADVANCES (2022)

Article Oncology

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Wolfgang P. Fendler, Kim M. Pabst, Lukas Kessler, Pedro Fragoso Costa, Justin Ferdinandus, Manuel Weber, Maria Lippert, Katharina Lueckerath, Lale Umutlu, Karina Kostbade, Ilektra A. Mavroeidi, Martin Schuler, Marit Ahrens, Christoph Rischpler, Sebastian Bauer, Ken Herrmann, Jens T. Siveke, Rainer Hamacher

Summary: This study reports the efficacy and safety of 90Y-labeled FAPI-46 in patients with advanced sarcoma, pancreatic cancer, and other cancers. The results show disease control in approximately 38% of patients, with a prolonged overall survival associated with disease control. However, there were adverse events observed, with thrombocytopenia and anemia being the most common.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents

Anna Boegelein, Antje Stolzenburg, Patrick Eiring, Katharina Luckerath, Umair Munawar, Rudolf Werner, Andreas Schirbel, Samuel Samnick, Klaus Martin Kortuem, Markus Sauer, Constantin Lapa, Andreas K. Buck

Summary: CXCR4 expression is highly variable and can be influenced by anti-myeloma drugs. Different drugs and doses have different effects on CXCR4 expression, with some drugs reducing expression while others increasing it. Combination of multiple drugs can further increase CXCR4 expression.

LEUKEMIA & LYMPHOMA (2022)

Meeting Abstract Oncology

Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities

R. W. Hamacher, K. M. Pabst, L. Kessler, P. F. Costa, J. Ferdinandus, M. Weber, M. Lippert, K. Lueckerath, N. Hirmas, K. Kostbade, I. A. Mavroeidi, M. H. H. Schuler, M. Ahrens, C. Rischpler, S. Bauer, K. Herrmann, J. T. Siveke, W. P. Fendler

ANNALS OF ONCOLOGY (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225

Catherine Meyer, Vikas Prasad, Andreea Stuparu, Peter Kletting, Gerhard Glatting, Jonathan Miksch, Christoph Solbach, Katharina Lueckerath, Lea Nyiranshuti, Shaojun Zhu, Johannes Czernin, Ambros J. Beer, Roger Slavik, Jeremie Calais, Magnus Dahlbom

Summary: This study compared the biodistribution of PSMA-TO-1, PSMA-617, and PSMA-11 in mice and prostate cancer patients, and evaluated their therapeutic effects and dosimetry data. The results showed that PSMA-TO-1 had higher tumor uptake and better treatment efficacy in mice. However, PSMA-TO-1 also led to increased uptake and doses in organs such as the kidneys.

EJNMMI RESEARCH (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities

Nader Hirmas, Rainer Hamacher, Miriam Sraieb, Marc Ingenwerth, Lukas Kessler, Kim M. Pabst, Francesco Barbato, Katharina Lueckerath, Stefan Kasper, Michael Nader, Hans-Ulrich Schildhaus, Claudia Kesch, Bastian von Tresckow, Christine Hanoun, Hubertus Hautzel, Clemens Aigner, Martin Glas, Martin Stuschke, Sherko Kummel, Philipp Harter, Celine Lugnier, Waldemar Uhl, Marco Niedergethmann, Boris Hadaschik, Viktor Grunwald, Jens T. Siveke, Ken Herrmann, Wolfgang P. Fendler

Summary: This article presents an overview of a prospective registry study on fibroblast-activation protein inhibitor (FAPI) over a 3-year period, comparing tumor uptake in 68Ga-FAPI and 18F-FDG PET as well as FAP immunohistochemistry. The study found that 68Ga-FAPI had higher tumor uptake in pancreatic cancer and sarcoma compared to 18F-FDG, and also demonstrated improved tumor detection.

JOURNAL OF NUCLEAR MEDICINE (2023)

Article Oncology

Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response

Claire M. Storey, Mohamed Altai, Mesude Bicak, Darren R. Veach, Katharina Lueckerath, Gabriel Adrian, Michael R. McDevitt, Teja Kalidindi, Julie E. Park, Ken Herrmann, Diane Abou, Wahed Zedan, Norbert Peekhaus, Robert J. Klein, Robert Damoiseaux, Steven M. Larson, Hans Lilja, Daniel Thorek, David Ulmert

Summary: Noninvasive biomarkers for androgen receptor (AR) pathway activation are urgently needed to better monitor patient response to prostate cancer therapies. A novel PET modality targeting hK2 was found to accurately assess EBRT-induced AR activity, which can be used for monitoring treatment response and development of resistance.

MOLECULAR CANCER RESEARCH (2023)

Meeting Abstract Oncology

Inhibiting deoxycytidine kinase significantly inhibits tumor growth in xenograft models of castration resistant prostate cancer

Caius G. Radu, Kenneth A. Schultz, Katharina Luckerath, H. Michael Shepard, Johannes Czernin

CANCER RESEARCH (2022)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities

N. Hirmas, M. Ingenwerth, M. Sraieb, L. Kessler, K. M. Pabst, H. Lanzafame, K. Lueckerath, S. Kasper, M. Nader, H. Schildhaus, B. Hadaschik, V. Gruenwald, B. Von Tresckow, C. Hanoun, C. Aigner, M. Glas, K. Herrmann, J. T. Siveke, R. Hamacher, W. P. Fendler

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

PSMA-directed imaging and therapy of salivary gland tumors: a single-center retrospective study

C. Civan, S. Kasper, C. Berliner, P. Fragoso-Costa, V. Gruenwald, M. Pogorzelski, B. M. Schaarschmidt, S. Lang, D. Kersting, M. Nader, K. Lueckerath, K. Herrmann, W. P. Fendler, M. Weber

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and cancer entities

W. Fendler, K. M. Pabst, L. Kessler, P. F. Costa, J. Ferdinandus, M. Weber, M. Lippert, K. Lueckerath, N. Hirmas, K. Kostbade, A. Mavroeidi, M. Schuler, M. Ahrens, C. Rischpler, S. Bauer, K. Herrmann, J. T. Siveke, R. Hamacher

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

FAPI, PSMA and FDG PET/CT in patients with advanced metastatic castration-resistant prostate cancer (mCRPC): a triple tracer comparison

K. M. Pabst, W. P. Fendler, B. Hadaschik, C. Kesch, N. Hirmas, L. Kessler, V. Gruenwald, R. Hamacher, M. Nader, C. Berliner, L. Umutlu, L. Puellen, K. Herrmann, K. Lueckerath, P. Castellucci, S. Fanti, R. Mei

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

No Data Available